title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab  ( Revised ) ,20240614T152100,https://www.zacks.com/stock/news/2288637/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab-revised,ESALF,0.195025,Somewhat-Bullish,0.250374
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune  ( Revised ) ",20240614T151000,https://www.zacks.com/stock/news/2288638/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune-revised,ESALF,0.176502,Somewhat-Bullish,0.233404
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune",20240613T100900,https://www.zacks.com/stock/news/2287623/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune,ESALF,0.18046,Somewhat-Bullish,0.23699
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab,20240612T142200,https://www.zacks.com/stock/news/2287324/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab,ESALF,0.199859,Somewhat-Bullish,0.254862
"The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity",20231212T141000,https://www.zacks.com/stock/news/2196695/the-zacks-analyst-blog-highlights-biogen-prothena-ac-immunes-and-vaxxinity,ESALF,0.04303,Neutral,0.124792
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus,20231211T140600,https://www.zacks.com/stock/news/2196083/alzheimers-disease-space-evolves-in-2023-stocks-in-focus,ESALF,0.04583,Neutral,0.124967
"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ",20231121T201625,https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o,ESALF,0.115787,Neutral,-0.048396
"Researchers return to Alzheimer's vaccines, buoyed by recent drug success",20231120T111500,https://www.reuters.com/business/healthcare-pharmaceuticals/researchers-return-alzheimers-vaccines-buoyed-by-recent-drug-success-2023-11-20/,ESALF,0.041682,Neutral,-0.028824
Biogen  ( BIIB )  & Eisai's Lecanemab Secures EMA's MAA Acceptance,20230127T145700,https://www.zacks.com/stock/news/2045510/biogen-biib-eisais-lecanemab-secures-emas-maa-acceptance,ESALF,0.239305,Somewhat-Bullish,0.268463
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,ESALF,0.056275,Neutral,-0.085904
"Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen",20220617T123100,https://www.zacks.com/stock/news/1940270/roche-alzheimers-candidate-failure-hurts-lilly-biogen,ESALF,0.160633,Neutral,0.004409
"Alzheimer's Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220505T112802,https://www.benzinga.com/pressreleases/22/05/g27015849/alzheimers-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,ESALF,0.031454,Neutral,0.021912
"Alzheimer Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220317T094130,https://www.benzinga.com/pressreleases/22/03/g26178322/alzheimer-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,ESALF,0.072032,Neutral,-0.132033
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,ESALF,0.013173,Neutral,0.040164
"Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket - AIM ImmunoTech  ( AMEX:AIM ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",20220928T111722,https://www.benzinga.com/news/22/09/29048520/why-mindmed-is-trading-lower-by-around-35-here-are-31-stocks-moving-premarket,ESALF,0.051111,Somewhat-Bullish,0.187436
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,ESALF,0.025139,Neutral,0.034515
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,ESALF,0.046184,Neutral,-0.032778
